Subtext

MOH

Molina Healthcare, Inc.2024 Q1

SectorHealth Care
Date2024-04-25
Overall sentiment-0.7
Total words4223
CEO words1847
CFO words862
Analyst words1109
Trailing EPS$21.58
Forward EPS est.$24.54
Forward P/E16.5
Sourceglopardo

Transcript

Each turn shows the speaker, their inferred role, the section, and that turn's net sentiment (×1000).

OperatorOperator+0.0

Hello, and welcome to the Molina Healthcare First Quarter 2024 Earnings Call. [Operator Instructions] Please note this event is being recorded. I would now like to turn the conference over to your host today, Jeffrey Geyer. Please go ahead.

Jeffrey GeyerOther+0.0

Good morning, and welcome to Molina Healthcare's First Quarter 2024 Earnings Call. Joining me today are Molina's President and CEO, Joe Zubretsky; and our CFO, Mark Keim. A press release announcing our first quarter 2024 earnings was distributed after the market closed yesterday and is available on our Investor Relations website. Shortly after the conclusion of this call, a replay will be available for 30 days. The numbers to access the replay are in the earnings release. For those of you who listen to the rebroadcast of this presentation, we remind you that all of the remarks are made as of today, Thursday, April 25, 2024, and have not been updated subsequent to the initial earnings call.

Joseph ZubretskyCEO+11.8

Thank you, Jeff, and good morning. Today, I will cover our traditional quarterly topics, our reported financial results for the first quarter, which were in line with our expectations, highlighted by $5.73 of earnings per share. An update on our guidance, which we reaffirm at $38 billion of premium revenue and at least $23.50 in earnings per share and an update on our growth initiatives, which in the quarter were mixed, but we are maintaining our $4 per share estimate of embedded earnings and our long-term growth outlook.

Mark KeimCFO+31.2

Thanks, Joe, and good morning, everyone. Today, I'll discuss additional details on our first quarter performance, the balance sheet, our 2024 guidance and thoughts on embedded earnings. Beginning with our first quarter results. For the quarter, we reported approximately $10 billion in total revenue and $9.5 billion of premium revenue with adjusted EPS of $5.73. Our first quarter consolidated MCR was 88.5% and reflect continued strong medical cost management.

OperatorOperator-83.3

[Operator Instructions] And today's first question comes from Kyle Sternick with JPMorgan.

Kyle KristickOther+25.2

I guess, first, I wanted to start on the guidance here, is -- you talked about the strength in the core business and the MCR sort of being in line with your expectations. So I guess, is the right way to think that the strength is really coming from G&A? And then when we think about the back half is -- I guess, is the outperformance in the current business enough to allow you to maintain guidance? Or if you think about the -- those potential contracts going away, are there additional SG&A savings you'd need to target in the back half to be able to offset those losses? Just any color to help us frame that would be great.

Joseph ZubretskyCEO+0.0

Okay. We are clearly saying that if we have a revenue loss in the third and fourth quarters due to the contract losses and the related earnings, the strength of the core business will produce enough earnings power to offset that. And it's no one thing. It's just general performance of all our portfolios. The loss ratios in our Medicaid and Medicare business get better as the year progresses for a variety of reasons.

Kyle KristickOther+0.0

Got it. And then I wanted to ask about the SNP regs as well. Specifically, how does that change your strategic thinking about M&A. I mean, I think the bright deal is really the first big Medicare asset begun purchased. Does this change the way you think about whether you'd be more biased towards MA or Medicaid? Or is it really just more motivation to sort of double down on the organic growth? .

Joseph ZubretskyCEO+34.2

It doesn't really change our M&A strategy. I mean we look for opportunities across all of [indiscernible], most of our M&A activity has been in Medicaid, but the Bright acquisition represents first M&A opportunity that we actioned in Medicare. But what we're really saying is the fact that we have this 20-state footprint in Medicaid and growing. The decent opportunity is just one more way to monetize your significant Medicaid footprint. And the fact that we have a very robust and very operationally excellent decent business. Those 2 platforms combined will allow us to participate in the duly eligible population growth rate that's going to happen here over the next number of years. So we're very, very pleased with the final rule that came out from CMS, which basically says that Medicaid will be the anchor tenant for action in the dual eligible population.

OperatorOperator-100.0

The next question comes from Josh Raskin with Nephron Research.

Joshua RaskinAnalyst+0.0

Just to go back on the Virginia and Florida. I heard the $0.80 from Texas and then the offset Virginia, Florida. Is that $0.80 an annual number? And is it, say, $0.40, $0.45 for 2024 specifically? And then just a second question on the M&A pipeline, a follow-up there as well. I'm curious if your experience with the acquisition of Bright and then the 2025 rate update. Has that changed the way you thought about Medicare Advantage?

Joseph ZubretskyCEO-62.5

I'll kick it to Mark for the question on the Florida and Virginia earnings. Go ahead.

Mark KeimCFO-7.7

On Virginia and Florida, just to set the stage, we think right now, that's about a $2 billion revenue run rate and about $1.10 on EPS full year. Now the simplifying assumption is we lose both in the fourth quarter, the headwind would be $0.5 billion on revenue and $0.30. But look, we're still working that through. Those are under protest and exactly what the timing is, is somewhat unclear. But if you deposit that assumption, it would be a $0.30 component to this year's guidance. which, as we mentioned in our prepared remarks, is offset by the underlying strength of the business. So if the full run rate is $1.10, we recognized $0.30 this year, what's left is $0.80 for embedded earnings. -- and that is exactly offset by the $0.80 of accretion we see in STAR and CHIP.

Joseph ZubretskyCEO+0.0

Josh,and your second question related to Bright now that we've owned the business for a full quarter, we are very optimistic and confident in the $1 of ultimate accretion. The way to think about that business is actually very simple. Operationally breakeven in year 1 with a slight earnings drag related to the carrying costs, breakeven in your -- operationally breakeven in year 2. And full $1 accretion in year 3 and we get there by -- we inherited a 95% MCR in the business. We've managed it to 87%. We inherited a 13% G&A ratio in the business. We managed to 8%, that's 1,300 basis points of turnaround, which on $1.6 billion of revenue would show you how we get to the full accretion.

OperatorOperator-90.9

And the next question comes from Stephen Baxter with Wells Fargo.

Stephen BaxterAnalyst-13.9

Two questions for you. Just first, I was hoping you could potentially spike out the new store Medicaid impact to MLR? And then when you think about the 90 basis point improvement that you're talking about, how much of that is normal seasonality versus maybe new store coming down or maybe just getting back some of the last bit of acuity adjustment? And then the second question is just on the Medicaid deal pipeline. I think your last announcement on that front? I know they still take a long time to close was in July, I think, 2022. I was just wondering if you could give us an update on the pipeline there? And it seems like maybe there's been some slowdown maybe as reformation distribution, maybe it's now just kind of hear when you think about the pipeline in Medicaid over the next 6 to 12 months.

Joseph ZubretskyCEO-10.8

Stephen, I'll answer the first question first and then kick it to Mark on the Medicaid MCR. The Medicaid MCR of 89.7% in the quarter was as expected and heavily influenced by 20% of the member month volume in the quarter was on new business, either new business that came in from California and Nebraska on [ 11 ] or our -- second half of our Iowa contract from 2023 in the My Choice acquisition. That new business runs in the '90s. So you can do the math. That created pressure on the Medicaid MCR in the first quarter.

Mark KeimCFO-19.4

Stephen, I'd just add to that. A year ago, our Medicaid MCR was 88.4%. This quarter, the legacy NCR was very close to that. So as Joe mentioned, coming out at 89.7% is a function of that new store MCR, which comes in hot. And recall, we said that this year, margins and earnings were a little bit back-end loaded consistent with our expectations. We came out really right where we expected. On the deal pipeline, I wouldn't say it slowed down. It's always fits and starts. What's most important to Joe and I is we constantly have a pipeline of advanced stage discussions.

OperatorOperator-90.9

The next question comes from Kevin Fischbeck with Bank of America.

Kevin FischbeckAnalyst+13.9

Can you talk a little bit about how redeterminations are going, both from the Medicaid and the exchange side of things. It sounds like you're 90% done, but you still expect strong growth on the exchanges. I guess when should that tailwind kind of be fully into the numbers? And then on the Medicaid side, you talked about a 30% recapture rate. Just trying to see any details about the acuity of that population.

Joseph ZubretskyCEO-44.9

I'll start off and then I'll kick it to Mark, but just to recap the entire redetermination process from start to finish. We estimate that at the high of the PHE, we have grown 1 million members due to the pause in the redetermination process. We are now projecting to lose 600,000 of those, 550,000 lost to date, another 50,000 in the second quarter. we have been experiencing a 30% reconnect rate. And once the redetermination process stops, that reconnect rate will continue on into the late spring and perhaps even into the summer.

Mark KeimCFO-23.1

Yes. If you look at our marketplace, we reported 346,000 members in the first quarter. We'll go to 370,000 per our original guidance. That's unchanged. And that's on the continued strength of folks coming in from redeterminations, which is obviously an anomaly this year. Remember, Marketplace always had normal lapses through the year. So typically, marketplace volumes declined through the year. in this case, will increase through the year to our guidance of 370,000.I think you asked about the reconnect rate. We're still seeing 30% on reconnects coming back in. And both the folks coming in to marketplace as well as the reconnects, we're not seeing an anomaly on the MORs that would really change our outlook for the year. So pretty much right on track, Kevin, right where we want to be. .

OperatorOperator-90.9

And the next question comes from A.J Rice with UBS.

Albert RiceAnalyst+8.5

Thanks. Hi, everybody. Maybe just to follow on that last train of thought, but a little different focus. Obviously, as we move into next year, you'll have given the redeterminations will subside as we get through the summer. you'll have the full impact of whatever change on the acuity risk pool there is, for legacy, people to stay on the Medicaid. When you sort of look at that at this early date, you got -- you signaled that you got these decent rate increases proactively in 17 states this year. Do you need a second year, do you think, of above-average rate increases when that acuity is fully reflected in the run rate for all of next year?

Joseph ZubretskyCEO+11.2

Let me recap where we are in the rate environment, and then I'll kick it to Mark for some more color. We couldn't be more pleased with the way our state customers have responded to having rates be commensurate with normal cost trends and trends that have been influenced by the acuity shift. We received acuity-related adjustments in 19 states, representing 95% of our revenue. We had 5 retroactive rate adjustments, and we're actually anticipating perhaps 4 more. So the states have been very responsive and rates have been actual really sound.

Mark KeimCFO+10.3

You mentioned the rate increase is kind of proactive, there probably more reactive, right, as so many of the states react to observe trends as opposed to proactively put it in. I wish they did. But as Joe mentioned, we're okay with the rate increases for this year. The rate increases we've seen look like they match the trend we're expecting. In we saw the acuity impact on trend really level off. And I think that's commensurate with the volume. So far, we've had 550,000 members leave only 50,000 were in this last quarter. So it's really leveled off.

Albert RiceAnalyst+0.0

Okay. And maybe if I could just ask on the Marketplace product. Obviously, the last 1, 1.5 years, you've been focused on repricing and margin. Now that you sort of have gotten that in place. Any update on your long-term strategy toward marketplace and growing that? Or what's your thought on that?

Joseph ZubretskyCEO+10.3

Sure. A.J., the small silver and stable strategy was a short-term reaction to having to re-position the business to maintain a profile of single digit -- mid-single digit pretax margins. That was a temporal way to look at the business. we invested about 300 basis points of what call excess margin from last year into the business this year, and that's why we're growing membership at 30% and premium revenues are growing at 20%. So we like the nice steady progression of the business. We do expect to grow it. But being in the insurance business as long as I have, you never try to grow any portfolio organically that quickly because when underwriting isn't allowed, which -- that's what this product is, you have to be very wary of where you're bidding against the market, who else is in the market and where your results are coming out for the prior year. So we're going to be cautious. But the nice steady growth we saw this year feels really good to us. We're able to maintain a profile of high single-digit pretax margins and grow at this rate I think that's what to expect.

OperatorOperator-100.0

The next question comes from Justin Lake with Wolfe Research.

Justin LakeAnalyst-13.0

A couple of questions here. First, last quarter, Joe, you mentioned an expectation that the company had visibility to grow EPS at the low end of your 15% to 18% outlook for 2025. Is that still the expectation? And then secondly, Joe, you mentioned that you're assuming in Texas or it looks like you're assuming in Texas that you get an average amount of share of the state from your new wins meaning there's 4 plants in a region, you get 25%.

Joseph ZubretskyCEO-6.0

Yes. Justin, the -- last quarter, we gave you the building blocks for an outlook into 2025, and we have not changed our view of those building blocks. Obviously, embedded earnings still at $4, we have actually changed the composition of that and how those emerge in upcoming years has changed slightly. But the building blocks haven't changed. We continue to harvest earnings out of our existing footprint. We talked about operating leverage, talk about embedded earnings. Obviously, there likely will be a natural headwind from interest rate declines into next year. So the building blocks haven't changed, and that's still our forward look for 2025, again, not guidance, but an outlook. On Texas, we don't know. We used very conservative estimates of what our market share would likely to be in the 7 regions that we won and use kind of the average portfolio margins. I don't think there's anything more to read into it than that. We think it's a conservative and reasonable estimate of what that business will produce.

Justin LakeAnalyst+0.0

So can you share that market share assumption?

Joseph ZubretskyCEO+0.0

I don't -- it's far too early, and we don't want to get ahead of our customer on that. So we'll wait and see until we have more visibility into how membership will be allocated. I think that's the prudent thing to do here.

OperatorOperator-100.0

The next question comes from Nathan Rich with Goldman Sachs.

Nathan RichAnalyst-11.5

I wanted to ask on Florida. Joe, I think you talked about the protests and the ultimate outcome could be different. I guess I'd be curious to get your view, Florida kind of shifted to more of a comprehensive care model in the state. And in your view, does that create, I guess, more friction than normal for the appeals process and potential changes there? And then as a follow-up, I wanted to ask if you had an updated view on the $46 billion revenue target by 2026.

Joseph ZubretskyCEO+7.4

In, on Florida, we're not making a prediction on how the process will unfold. We're citing historical precedent. Historical precedent would suggest that this is not the end, it's sort of the beginning of the end of the process. that there's more discussions that will take place. So I don't want to, again, get ahead of the state on this. But if you look at the past 2 procurements in Florida, there have been extended conversations and there are regions in Florida that still do not have maximum awards given. So again, just citing historical precedent. On the $46 billion of revenue, but we have a $60 billion new contract pipeline. Kansas and Georgia are sitting out there currently live and in process. as I mentioned, Texas STAR Kids. We have great momentum in the State of Texas.

OperatorOperator-100.0

The next question comes from Gary Taylor with TD Calin.

Gary TaylorAnalyst-20.6

I had 2 policy questions actually. One, just because I get asked a lot just about the expiring ACA credits for 2026, maybe leaving aside whether or not they get renewed and the politics of that. Just wondering, from a technical basis, how are you guys thinking about sort of elasticity of demand for exchange product, if some of the income level categories see a fairly material percentage change in the premium that would be required, just what you're thinking now, if end of the worst case, those went away. What the impact might be, how much is retained.

Joseph ZubretskyCEO+0.0

On the -- I believe your first question was on the enhanced subsidies for Marketplace. I understand it -- it's hard to say. -- bear in mind, they do go away unless legislation is passed to extend them. That's -- sometimes that's misunderstood. They are going away because the subsidy enhancement was temporary. and a less legislation is passed to extend them they will.

Gary TaylorAnalyst+0.0

The managed care, the Medicaid managed care access finance quality accrual that was out earlier this week.

Joseph ZubretskyCEO-7.2

Not significant. We're still analyzing it. We're obviously aware of it. We're analyzing it. lots of different features to it, many of which incept over very extended periods of time. So there's nothing to immediately react to. But nothing in that guideline changes of the long-term trajectory of the business. As I've said many times, I often asked, is there any political legislative or judicial environmental issue that causes you major concern on the viability of the businesses you're in. And the answer is no. The way the election comes out, whether Congress is split, whether things can get done vis-a-vis the 60 votes in the Senate needed to do something fundamental, the reconciliation process, et cetera. We don't -- we think the legislative and political scenarios are pretty neutral for the sustainability of the businesses we're in.

Mark KeimCFO+33.9

Gary, the one thing I would point out is certainly when they streamline Medicaid and chip eligibility and all the procedural items that folks have to go through to maintain or get eligibility, it just makes it easier for the appropriate coverage to go to the right people, and we think that's obviously a good tailwind for our business.

OperatorOperator-111.1

The next question comes from George Hill, Deutsche Bank.

George HillAnalyst+0.0

Joe, just a high-level question. One of your peers this week talked about a normalized individual MA margin of 3% or better. I know that your book of business is a little bit different. But I was just wondering if you guys would be willing to kind of speak to what you think the normalized margin profile of individual MA is and kind of how you think that varies between the D-SNP book and the individual book. And I know that you guys have a heavily subsidized population. So the book is a little bit different, but I appreciate any color.

Joseph ZubretskyCEO+0.0

Yes. Well, our target for our Medicare business is mid-single-digit pretax. I wasn't sure whether you're referring to pretax or after tax, our NCR range for the products we're in is 87% to 88%. As we said, we hope to get -- not hope. We're projecting to get right down to 87% here over the next couple of years. So we still target mid-single-digit pretax margins in this business.

Mark KeimCFO+20.4

George, the only thing I'd add is it's really hard to compare a Molina book of business to some of our big competitors in Medicare. Remember, we skew really heavily to the dual eligibles. So we've got an awful lot of our book in the high teens to $2,000 PMPMs, which are high acuity. If you're very good at managing medical costs -- there's a big opportunity on those high-dollar members to get to the margins that Joe talked about, even in the presence of some headwinds. So I think it's really hard to make that comparison to others.

OperatorOperator-100.0

And the next question comes from Scott Fidel with Stephens.

Scott FidelAnalyst+0.0

Two questions. The first one, just if you've gotten the scoring results yet from Florida and have been able to start to develop the factual points that may be the basis of your appeal in Florida is definitely interested in your thoughts on that? And then just second, on the HICS side, just if you want to refresh us at this point after seeing results so far, what you're expecting for full year MLR and pretax margin offer 2024 for the HICS business.

Joseph ZubretskyCEO-16.9

On these protest processes, I think I've said about all I really should say about them. They are legal processes, and we have to see how they unfold. But of course, through various requests, I'm sure everybody's got the information they need to document their findings and to put their case forward. So that's all I'll say about it.

Scott FidelAnalyst+0.0

Okay. Got it. So reaffirming the initial guidance you gave us for the exchange MLR margin?

OperatorOperator-100.0

And the next question comes from Andrew Mok with Barclays.

Andrew MokAnalyst+30.3

I think I heard you say that you're prudent in your reserves due to change. Was there any favorable PYD in the quarter? And if so, did you reestablish that into your reserves?

Mark KeimCFO+41.2

It's Mark. Yes, absolutely, there's favorable PYD, and you'll see that in the earnings release where we showed the prior year development on current year reserves. It tracks about as it normally does, not higher, not lower. And of course, we always replenish that. So we feel very confident I showed a 49% days claims payable, which is right in the middle of our standard range. We feel very good about our reserves even with a little bit of noise from the change situation that happened back in February. So very confident, reserves replenished, we feel adequately reserved.

Andrew MokAnalyst+0.0

Was there any P&L impact in the quarter from the PYD?

Mark KeimCFO+16.7

There always is. That's a normal part of a reserving cycle. Typically, the way you reserve is in the current period, you pick a number, which is generally a little bit conservative. And typically, prior periods developed favorably. That is a standard cycle of the actuarial and reserving process and how we recognize earnings. Nothing unusual there in this quarter.

OperatorOperator-90.9

And the next question comes from Sarah James with Cantor Fitzgerald.

Sarah JamesAnalyst+0.0

I wanted to clarify the mix on the 2026 revenue guide. So IDA, you guys talked about it being about 1/4 organic, quarter M&A and 50% contracts contract wins. Do you still see that as the mix? And then could you give us any clarity on your rate renewal timing? What percentage of your book renews in January versus April and September.

Joseph ZubretskyCEO+7.9

I'll answer the second question first. We have a really nicely laddered renewal pattern in our portfolio, which is great from a risk management perspective. of our revenue renews on January 1. 21% renews in the fall. The rest of it is [indiscernible] so the renewal pattern is nicely better throughout the year. Right now, given our guidance, we know 82% of rates, we know the rates on 82% of our revenue for this year's revenue guide, which leaves us very little rate risk to our forecast. That's the -- that's how we have great visibility. And as Mark said, if you get pressure, cost pressure, in the second half of the year. In fact, at 52% of the revenue then cycles into January 1, or we capture that nicely. Your other question was?

Sarah JamesAnalyst+0.0

Yes. On the $46 billion premium rev in 2026, do you think of it as the buckets that you laid out at I-Day, which was about 50% of the growth being from contract wins, 25% from M&A, 25% from organic?

Joseph ZubretskyCEO+19.0

Yes. I think that's nothing has caused us to change that outlook. I mean it's a very high-level outlook and more of it comes from M&A, that's fine. When you're buying the properties with the capital efficiency, we buy them at which we buy them. But that actual mix could change, but that's probably the way to think about it. That is the way we think about it. But again, if the mix changes, we have more contract wins and more M&A. It's all very accretive and as long as we're refilling the bucket of embedded earnings, we feel good about it.

OperatorOperator-37.0

And this concludes the question session as well as the call itself. Thank you so much for attending today's presentation. You may now disconnect your phone lines.